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retrospective US medicare claim base data analysis have been shown to signiﬁcantly 
decrease mortality risk of a VCF patient when treated with BKP compared to NSM. 
Aim of this study is the evaluation of resource usage and costs for treatment of BKP 
patients in comparison to NSM patients from a social insurance perspective. 
METHODS: In this prospective, non-randomised follow-up-study treatment and costs 
were evaluated in 8 study centers in Germany between 2005 and 2008. Data was 
recorded by questionnaires at baseline and by phone at follow-up. Resource usage 
was valued by DRG for inpatient treatment, EBM fur outpatient treatment and 
Lauer-taxe for medication. RESULTS: The higher initial DRG treatment costs in the 
BKP arm are partially off-set by lower follow-up costs (Follow-up DRG costs: BKP: 
a131.08; NSM: a1149.75; Mann-Whitney-U: p  0.006; Outpatient treatment: BKP: 
a860.57; NSM: a991.65; Mann-Whitney-U: p  0,300; Medication: BKP: a136.56; 
NSM: a338.42; Mann-Whitney-U: p  0.007). Total costs for the BKP patients were 
a 3,874.12 higher than for the NSM patients (Mann-Whitney-U: p  0.000). Compared 
to NSM, BKP treated patients had signiﬁcantly shorter hospital stay for both the initial 
and follow-up hospitalization (9.6 versus 14.7, p  0.000 and in follow-up hospitaliza-
tion 10.7 versus 17.7, p  0.005). CONCLUSIONS: The higher baseline costs of BKP 
versus NSM are partially off-set by reduced follow-up treatment costs. The remaining 
additional costs have to be weighted against shorter hospital stay and improved clinical 
outcomes. Full economic evaluations of BKP versus NSM in the UK, Italy and Spain 
have already demonstrated the cost-effectiveness of BKP versus NSM.
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OBJECTIVES: TNF-A inhibitors are becoming a widely used treatment option for 
rheumatoid arthritis (RA) in the South African private sector. Justiﬁcation for reim-
bursement decisions range from pure list price comparisons to cost of treatment com-
parisons, with limited use of health economics, since South African private health care 
funders have a developing understanding of health economics. The objective of this 
cost of treatment comparison is to estimate the total direct medical costs associated 
with the use of TNF-A inhibitors for the treatment of RA in the South African private 
sector. METHODS: This analysis compares the cost of treatment using the results of 
the DART dose escalation study comparing etanercept, adalimumab and inﬂiximab. 
The expected direct medical costs were estimated over a one year period under two 
scenarios (dose escalation and no dose escalation) and included the costs of TNF-A 
inhibitors, administration, consultation and dispensing. The scenario excluding dose 
escalation was based on minimum label dose and the dose escalation scenario was 
based on 12 months of actual dosing of each TNF-A inhibitor from the DART data. 
Cost values were estimated from the perspective of the South African private health 
care funder. RESULTS: Total direct medical costs associated with the use of etaner-
cept, adalimumab and inﬂiximab are respectively R118,235, R118,357 and R121,481 
per person based on the DART dose escalation study. The cost associated with adali-
mumab is 5% lower compared with etanercept and inﬂiximab when the effect of dose 
escalation is not taken into account. The total cost of treatment for the total popula-
tion of private sector RA patients using TNF-A inhibitors is 77 million ZAR (a6.9 
million). CONCLUSIONS: The direct medical costs associated with the use of TNF-A 
inhibitors for the treatment of RA patients in South Africa are similar despite the dif-
ferences in list prices of these agents.
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OBJECTIVES: To establish the total direct medical cost of patients in second-line TNF 
a therapy from the French heath care system perspective. METHODS: A multicentre 
observational study was conducted, recruiting patients treated since at least four 
months by a second TNF a therapy. The sample represented was assessed through the 
comparison of the regional allocation of inclusions to the regional allocation of TNF 
a prescriptions issued from a national panel. Inpatient and outpatient consumptions 
were collected retrospectively, for the preceding four months. Respect of clinical 
practice recommendations was assessed through the analysis of administration fre-
quencies and posologies. RESULTS: Fifty-nine hospital centres participated in the 
study, including 277 patients. The sample could be considered as representative as 
the correlation between the regional activity in terms of TNF a prescriptions and the 
number of included patients per region was high (r  0.88). The resulting total annual 
direct medical cost equalled a16,000 per patient. Respectively 43, 132, and 102 
patients were included in the INF, ETA and ADA groups. Two patients treated 
by INF received more than the expected number of administrations, whereas 8 others 
had a higher dosage than that recommended. Respectively 11.4% and 24.5% of 
patients treated by ETA and ADA also received more administrations than expected 
during the 4 months of treatment. CONCLUSIONS: This representative study 
stated that hospitalisation costs represented 92% of the total direct medical costs of 
patients treated by a second-line TNF a therapy, reaching a16,000 per patient and 
per year. In the absence of a speciﬁc market authorisation in the indication, TNF a 
therapies are prescribed, but the clinical practice recommendations are not always 
respected.
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OBJECTIVES: to examine the cost-beneﬁt of management strategies for reducing road 
trafﬁc injuries. METHODS: The study was a cross-sectional analysis of secondary 
data retrieved from the Injury Surveillance (IS) in the ﬁscal year 2004 to 2006. The 
sample consisted of all trafﬁc accidental patients who received hospital emergency 
services. The two dependent variables used were direct medical cost and death, mul-
tiple linear regression models and binary logistic regression models were constructed. 
The outputs of management strategies: non-use of crash helmets and drunk driving 
were explained by using Monte Carlo technique. RESULTS: The study covered 12,651 
patients. For the regression analysis, statistically signiﬁcant predictors were composed 
of sex, age, drunk driving, non-use of crash helmets, accidental timing, victim and 
severity (adjusted R2  0.60). For the binary logistic regression analysis, odd-ratio of 
the causes of death of non-use of safety equipments (helmet and seatbelt) and drunk 
driving were 3.56 (CI 2.62–4.85) and 1.24 (CI 1.01–1.53) respectively. The direct 
medical cost arrived at from using the regression model when using law enforcement 
with 50 percent succession of both strategies was THB20,983,413.59. Compare with 
the current situation, it was THB26,709,449.76 (21.44% save). In the same way, the 
net beneﬁt gain from these enforcement was THB512,894,977.48. (58.44% save). 
Nevertheless, changing each assumption of the successful management strategies from 
10% to 50%, the sensitivity analysis shows the range of saving from 24.67% to 
58.44% and the beneﬁt to cost ratio was 10.81. CONCLUSIONS: These ﬁndings 
show the scenario to reduce trafﬁc injury, the law enforcement strategies for using 
safety equipment and reduce the number drunk driving is a useful management tool 
to reduce cost of illness nearly three-quarters of the damages from road trafﬁc 
injuries.
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OBJECTIVES: Biologic agents are commonly used sequentially to treat moderate to 
severe rheumatoid arthritis (RA). In absence of clinical trials comparing biologic 
strategies, simulation models are useful to inform decisions. The objective is to 
assess, using the NHS perspective, the cost-effectiveness of biologic strategies in 
patients with an insufﬁcient response (IR) to at least 1 anti-TNF agent. METHODS: 
Simulation models were developed to assess four strategies of different biologic agents 
over 2 years. Assuming an IR to the 1st anti-TNF agent, Sequence 1 included etaner-
cept-abatacept-adalimumab and Sequence 2 etanercept-rituximab-adalimumab. 
Assuming an IR to 2 anti-TNF agents, Sequence 3 included etanercept-adalimumab-
abatacept and Sequence 4 etanercept-adalimumab-inﬂiximab. Effectiveness data was 
derived from published evidence based on achieving a low disease activity state 
(LDAS). Switch occurred at each 6 months in case of an IR to the previous agent. 
UK direct medical costs and biologic drug costs were used. Extensive probabilistic 
sensitivity analyses were performed. RESULTS: There were 6-month medical costs 
(excluding biologic drug costs) were estimated at £1047 (Standard Deviation [SD] 
332) for managing patients in LDAS and at £2650 (SD 963) for moderate-to-high 
disease activity. Over 2 years, Sequence 1 appeared more efﬁcacious (92 days in LDAS) 
versus Sequence 2 (82 days in LDAS,) with cost-effectiveness ratios of £281/day in 
LDAS vs. £289/day in LDAS, respectively. Sequence 3 appeared more efﬁcacious (43 
days in LDAS or) vs. Sequence 4 (32 days in LDAS), with cost-effectiveness ratios of 
£603/day in LDAS vs. £809/day in LDAS, respectively. CONCLUSIONS: Medical 
costs associated with moderate-to-high disease activity are estimated to be 2.5 times 
higher than for LDAS, suggesting that efﬁcacious treatment strategies contribute to 
reducing use of health care services. The results of this simulation model suggest that, 
for achieving LDAS, sequences including abatacept after an IR to at least 1 anti-TNF 
agent appear more cost-effective than similar sequences including rtx or cycled anti-
TNF agents.
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OBJECTIVES: Several studies have demonstrated that compliant and long-term use 
of bisphosphonates is necessary to realize full beneﬁts of treatment. In particular, a 
progressive relation between compliance (medication possession ratio above 80%) and 
fracture risk reduction has been found (Siris, Mayo Clin Proc 2006;81:1013–22 and 
Penning, Osteoporos Int 2008;19:511–17). Taking into account patient compliance, 
we compared the effectiveness and costs of zoledronic acid (ZOL) versus weekly 
alendronate & risedronate and monthly ibandronate therapies over 3 years in the 
prevention of postmenopausal osteoporotic fractures from the NHS perspective of 
Turkey, using Number Needed to Treat (NNT) approach. METHODS: NNT values 
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(1 / (placebo fracture risk – treatment fracture risk) for vertebral (VF), non-vertebral 
(NVF) and hip fractures (HF) were derived as a function of fracture risks and compli-
ance rates associated with each therapy. Both drug costs and efﬁcacies were adjusted 
to compliance rates. Relative risks and placebo incidences of each fracture type 
were obtained from the clinical trials, meta-analyses from NICE reviews, and costs 
were gathered from local price database. Annual compliance rates were taken from 
the literature (Willemijn, Cur Med Res Opin 2008;24:3217–22). RESULTS: Com-
pared to each oral bisphosphonate (OB), ZOL generated the lowest clinical NNTs 
for all fracture sites. Under conservative compliant patient rate of 50% for weekly 
and 75% for monthly OBs, cost of treatment to prevent one fracture in 3 years 
was a30,625 (VF) and a160,400 (HF) for ZOL; a76,800 (VF) and a272,900 (HF) 
for branded alendronate; a75,825a (VF) and a269,325a (HF) for generic alendronate; 
a170,250 (VF) and a783,400 (HF) for risedronate; and a65,725 (VF) for ibandronate. 
Sensitivity analyses were performed. CONCLUSIONS: In the Turkish setting, 
compared to all OBs once-yearly administered ZOL was dominantly the most 
cost-effective treatment regardless of fracture type upto a level of 90% compliance 
with oral therapies.
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OBJECTIVES: To evaluate the cost effectiveness of zoledronic acid 5 mg once yearly 
compared to generic alendronate in postmenopausal patients with osteoporosis. 
METHODS: A cost effectiveness model, based on the model used in the NICE apprais-
als of the cost effectiveness of osteoporosis treatments in postmenopausal women at 
increased risk of fracture, was adapted to the Danish setting. Lifetime costs and quality 
adjusted life years (QALYs) were calculated assuming ﬁve years of treatment. Relative 
risks of fracture protection were obtained from the HORIZON-PFT trial for zole-
dronic acid 5 mg, and from meta-analyses from NICE reviews for generic alendronate, 
assumed to be equal to branded alendronate. Compliance with zoledronic acid was 
assumed to be 100% (by deﬁnition of a once-yearly infusion) and sensitivity analyses 
were conducted for the compliance with generic alendronate, with decreased efﬁcacy 
extrapolated from the relationship between compliance and probability of fracture 
(Siris, 2006). Costs of fractures were taken from Danish cost studies and/or DRG cost 
lists and pharmacy costs of the medications were based on ofﬁcial list prices. Utilities 
were obtained from the literature. RESULTS: For patients 70 years old with a T-score 
of 2.5, zoledronic acid dominated generic alenronate when compliance with generic 
alendronate was 70% or lower. The dominating cost effectiveness of zoledronic acid 
over generic alendronate increased with decreased generic alendronate compliance, 
with incremental cost effectiveness ratios (ICERs) of between 5.077 DKK for 70% 
compliance and 48,202 DKK for 50% compliance. CONCLUSIONS: A single annual 
infusion of zoledronic acid 5 mg provides cost savings over daily generic alendronate, 
assuming a conservative real-life compliance of 70% for generic alendronate. There-
fore, despite the availability of cheaper generics, their poor compliance results in cost 
savings for a more expensive alternative with better compliance. Further data is needed 
to make conclusions on longer term implications.
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OBJECTIVES: Evaluate the cost-effectiveness of dabigatran etexilate compared with 
enoxaparin for the primary prophylaxis of venous thromboembolism (VTE) after total 
hip replacement (THR) or total knee replacement (TKR) in Spain. METHODS: A 
published cost-effectiveness model was adapted to the perspective of the Spanish 
National Health Service. Oral dabigatran etexilate 220 mg/day was compared with 
injectable enoxaparin 40 mg/day. The efﬁcacy and safety of the treatments was deter-
mined from two pivotal phase III studies comparing these interventions. The model 
combined a decision tree for the peri-operative period (acute phase, 10 weeks) with a 
Markov model for long-term events (chronic phase, 60 years). The treatment patterns, 
consumption of resources and costs were based on quantitative (databases, patient 
registries, ofﬁcial statistics) and qualitative (systematic literature review, expert 
surveys) data sources for Spain. Univariate deterministic and probabilistic sensitivity 
analyses were performed. RESULTS: The study results suggest that overall outcomes 
do not differ signiﬁcantly between dabigatran etexilate and enoxaparin. Mean Life 
years were 0.018 and 0.020 higher for dabigatran patients undergoing THR and TKR 
respectively; mean QALYs were 0.013 and 0.015 higher respectively. Mean overall 
costs were lower for dabigatran patients by a189 and a53 respectively. In the proba-
bilistic sensitivity analysis, dabigatran etexilate was dominant for most of the one 
thousand simulations in THR. The probability that dabigatran is cost-effective at a 
threshold of a30,000/QALY was 99% in THR and 87% in TKR. In the deterministic 
sensitivity analysis, dabigatran was dominant versus enoxaparin in all scenarios in 
both THR and TKR. CONCLUSIONS: From the viewpoint of the Spanish NHS, 
primary prophylaxis with dabigatran etexilate (220 mg/day orally) has a lower cost 
than enoxaparin (40 mg/day subcutaneously) after THR and TKR with a comparable 
efﬁcacy and safety proﬁle.
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OBJECTIVES: The management of moderate to severe rheumatoid arthritis includes 
the use of biologic agents. Modelling allows simulation of complex biologic treatment 
strategies after an insufﬁcient response (IR) to previous biologic agents. The objective 
is to assess the cost-effectiveness of various biologic treatment sequences over two 
years according to the Turkish health care system using a public payer perspective. 
METHODS: Six treatment strategies using three successive biologic agents [etanercept 
(ETA), adalimumab (ADA), inﬂiximab (INF), abatacept (ABA) or rituximab (RTX)], 
were modelled based on Turkish medical practice. Effectiveness was derived from 
published evidence as expected number of days in low disease activity state (LDAS). 
Biologic treatment was maintained for achieving LDAS or switched at each six months 
in case of IR. Total medical costs were estimated per level of disease activity over 6 
months. Extensive probabilistic sensitivity analysis was performed. RESULTS: Con-
sidering an IR to 1 anti-TNF agent, the sequence ETA-ABA-ADA was more efﬁcacious 
and cost-effective (102 days in LDAS; 496 TL per day in LDAS) over 2 years than 
the sequence ETA-RTX-ADA (82 days in LDAS; 554 TL per day in LDAS or 81 days 
in LDAS; 563 TL / day in LDAS based on RTX current reimbursement status). Con-
sidering an IR after 2 anti-TNF agents, the sequences ETA-ADA-ABA and ETA-INF-
ABA were more efﬁcacious and cost-effective (64 days in LDAS for both; 841 and 
826 TL / day in LDAS, respectively) over 2 years than a sequence of anti-TNF agents 
only (32 days in LDAS; 1480 TL per day in LDAS). CONCLUSIONS: These simula-
tions suggest that over two years of therapy, sequences including abatacept after an 
IR to one anti-TNF agent are more efﬁcacious and cost-effective vs. similar sequences 
including rituximab. Sequences including abatacept after an IR to 2 anti-TNF agents 
also appear more effective and cost-effective than similar sequences composed of anti-
TNF agents only.
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OBJECTIVES: Progressive Rheumatoid Arthritis (RA) usually requires different thera-
peutic options used sequentially in case of an insufﬁcient response (IR) to previous 
agents. As clinical trials comparing biologic treatment sequences are lacking, simula-
tion models inform on optimal treatment sequences and their cost-effectiveness. The 
objective was to assess the cost-effectiveness of different biologic treatment strategies 
based on levels of disease activity using the perspective of the German public payer. 
METHODS: A cost-effectiveness sequential model was developed based on RA treat-
ment goals, using DAS28 scores as dichotomous endpoints: remission/no remission or 
Low Disease Activity State (LDAS)/no LDAS. Costs were estimated using a re-analysis 
of the published ‘ Hannover costing study’. Advanced simulations were conducted to 
assess the cost-effectiveness over 2 years of four sequential biologic strategies com-
posed of anti-TNF agents, abatacept and rituximab, in patients with moderate to 
severe active RA and an IR to at least one anti-TNF agent. RESULTS: Medical costs 
for patients in LDAS, remission or in moderate to high disease activity were estimated 
at a3929 (SD  8566), a4853 (SD  13488) and a7017 per 6 months (SD  11813), 
respectively. Over 2 years, the sequence with abatacept after 1 anti-TNF agent 
appeared the most effective and cost-effective, vs. use after 2 anti-TNF agents (a633 
vs. a1067/day in LDAS and a1222 vs. a3592/day in remission), and vs a similar 
sequence using rituximab (a633 vs. a728/day in LDAS and a1222 vs. a1812/day in 
remission). The sequence using a 3rd anti-TNF agent was less effective and cost-effec-
tive than the same sequence using abatacept (a2000 vs. a1067/day in LDAS and a6623 
vs. a3592/day in remission). CONCLUSIONS: Achieving LDAS or remission is associ-
ated with lower medical costs than high disease activity states. The results suggest that 
in patients with an IR to at least one anti-TNF agent, biologic sequences including 
abatacept appear more efﬁcacious and cost-effective than similar sequences including 
rituximab or cycled anti TNF agents.
